Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

Clinical value of whole-body PET/CT in patients with active rheumatic diseases. - Clinical value of whole-body PET/CT in patients with active rheumatic diseases.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022735

Enrollment

100

Registered

2016-09-01

Start date

2016-09-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic diseases

Interventions

FDG-PET/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Pregnancy Patient who can not keep still during the examination

Design outcomes

Primary

Measure	Time frame
FDG uptake in site of lesion (visual assessment, SUV quantification)	—

Secondary

Measure	Time frame
Disease activity	—

Countries

Japan

Contacts

Public ContactHiroyuki Yamashita

National Center for Global Health and Medicine Division of Rheumatic Diseases

hiroyuki_yjp2005@yahoo.co.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026